Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Kailera Therapeutics, Inc.NASDAQ: KLRA
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) of -$1.09 in Q2 FY2026
Q2 FY2026 EPS (Basic) was -$1.09.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 2 analysts of -$3.61 (-186.2%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$1.09-62.7% QoQ
- Last fiscal yearDec 2025
- -$1.26— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | -186.2% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.26) USD
- Year-over-year change
- —
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.26) | — |
EPS (Basic) vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 EPS (Basic) of -$1.26 is the 5th highest of the 10 companies compared; the peer median is -$1.74.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.65 | +473.2% | — | |
| LTM Mar 2026 | $0.02 | +100.6% | — | |
| LTM Mar 2026 | -$0.89 | +75.0% | — | |
| LTM Mar 2026 | -$0.93 | +26.2% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | -$1.26 | — | — |
| LTM Mar 2026 | -$1.74 | +5.4% | — | |
| LTM Jun 2026 | -$2.18 | -32.1% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$2.4 | -18.2% | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$3.06 | -28.0% | — |
| LTM Jun 2026 | -$4.66 | -204.6% | — | |
| Peer median (excluding KLRA) | -$1.74 | +5.4% | — | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| Weighted Avg Shares | 117.95M |
| Weighted Avg Shares (Diluted) | 117.95M |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.